Premium
The pharmacogenetics of antidepressant treatments for depressive disorders
Author(s) -
Lee MinSoo
Publication year - 2005
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20020
Subject(s) - antidepressant , serotonin transporter , pharmacogenetics , tryptophan hydroxylase , pharmacology , serotonin , major depressive disorder , medicine , psychology , psychiatry , receptor , genotype , biology , genetics , serotonergic , gene , anxiety , cognition
Pharmacological treatments for depressive disorder vary between individuals, with 30–40% of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold‐standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G‐protein β subunit, and the norepinephrine transporter. Drug Dev. Res. 65:170–178, 2005. © 2005 Wiley‐Liss, Inc.